Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0017 | 0 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0017 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0017 | 0 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0017 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0017 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0017 | 0 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0017 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0017 | 0 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0017 | 0 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0017 | 0 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0017 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0017 | 0 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0017 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0017 | 0 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0017 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.